- \n
- \nCEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 \u2014 Open to Investors, Researchers, and the Global Biomedical Community<\/p>\n<\/li>\n
- \nRegistration Link & Details Can be Accessed Below<\/p>\n<\/li>\n<\/ul>\n
DALLAS–(BUSINESS WIRE<\/a>)–
\nLantern Pharma Inc. (NASDAQ: LTRN) (\u201cLantern\u201d or the \u201cCompany\u201d), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai<\/b>, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform’s scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite \u2014 and marks the first time the platform will be demonstrated live and without restriction to a global public audience of investors, researchers, and industry participants.<\/p>\n\nPresident and Chief Executive Officer Panna Sharma will lead the demonstration in real time \u2014 live, interactive, and unrehearsed \u2014 showing how withZeta.ai operates as a genuine AI co-scientist at the frontier of oncology drug discovery. Two identical sessions will be held to accommodate global time zones:<\/p>\n
- \n
- Morning Session: <\/b>8:30 AM ET \u2014 Register Here<\/a><\/li>\n
- Afternoon Session: <\/b>4:30 PM ET \u2014 Register Here<\/a><\/li>\n<\/ul>\n
\nEach session will include a live platform walkthrough followed by an open Q&A with management.<\/p>\n
From Scientific Validation to Public Stage<\/b><\/p>\n
\nwithZeta.ai made its scientific debut at AACR 2026 \u2014 one of the world’s most rigorous forums for oncology and translational research \u2014 and was first unveiled at Nasdaq MarketSite, a globally recognized venue at the intersection of capital markets and innovation. April 30th represents a deliberate next step: opening the platform to the full public for the first time, with no gatekeeping, no curated excerpts, and no pre-recorded footage.<\/p>\n
\nAttendees will watch in real time as the platform executes complex research workflows \u2014 synthesizing clinical, molecular, and scientific datasets simultaneously to generate insights and compress research timelines that historically required months of manual effort. This is not a product marketing event. It is a transparency event, and the platform will speak for itself.<\/p>\n
A Platform Built for the Economics and Urgency of Rare Cancer<\/b><\/p>\n
\nWith the AI-driven drug discovery market projected to surpass $15 billion by 2030 and growing at over 30% annually, the industry is in the early stages of a structural transformation. Yet rare cancers remain the discipline’s most persistent blind spot \u2014 historically neglected not for lack of scientific interest, but because the economics and timelines of traditional development make them commercially unattractive.<\/p>\n
\nwithZeta.ai was purpose-built to close that gap. The platform integrates:<\/p>\n
- \n
- \nA proprietary rare cancer ontology spanning hundreds of cancer subtypes, structuring biological knowledge in a form that AI agents can actively reason across \u2014 not merely retrieve.<\/p>\n<\/li>\n
- \nMulti-database querying across clinical trial registries, biomedical literature, and molecular datasets \u2014 simultaneously and in real time, not sequentially.<\/p>\n<\/li>\n
- \nAdvanced generative AI models for molecular design, ADMET prediction, blood-brain barrier permeability analysis, and structure-activity relationship (SAR) evaluation \u2014 capabilities embedded in the platform\u2019s Ether0 generative chemistry architecture.<\/p>\n<\/li>\n
- \nA scalable, subscription-based commercial model \u2014 with introductory, academic, and enterprise tiers \u2014 representing a non-dilutive, recurring revenue stream accessible to any researcher, institution, or biopharma organization globally.<\/p>\n<\/li>\n<\/ul>\n
\nFollowing its debut at Nasdaq MarketSite and AACR 2026, Lantern is advancing withZeta.ai as both a scientific accelerator and a commercial growth engine \u2014 one that creates value for rare cancer patients, for research institutions, and for Lantern shareholders simultaneously.<\/p>\n
\u201cThe rarest cancers have always faced the longest waits \u2014 not because the science is absent, but because the infrastructure to move at the speed of urgency has never existed. withZeta.ai changes that. It is not a search engine, not a literature tool, and not a chatbot with oncology data loaded in. It is a multi-agentic AI-powered co-scientist, forged from years of real clinical development, careful curation of knowledge-bases and exquisite disease models. It is capable of executing research workflows and drug development decision making and assessment in real time – things that would otherwise take months or longer. On April 30th, we are inviting the world to see it operate \u2014 live, unrehearsed, and without restriction.\u201d<\/i><\/p>\n
\u2014 Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.<\/i><\/b><\/p>\n
Webinar Access Details<\/b><\/p>\n
Date: <\/b>Thursday, April 30, 2026<\/p>\n
Morning Session: <\/b>8:30 AM ET<\/p>\n
- \n
- Registration: <\/b>Register for Morning Session<\/a><\/li>\n<\/ul>\n
Afternoon Session:<\/b> 4:30 PM ET<\/p>\n
- \n
- Registration: <\/b>Register for Afternoon Session<\/a><\/li>\n<\/ul>\n
Subscribe Now: <\/b>withZeta.ai<\/a><\/p>\n
ABOUT LANTERN PHARMA INC.<\/b><\/p>\n
\nLantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR\u00ae platform to transform the development of cancer therapies. Lantern\u2019s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic cancers and sarcomas), and LP-300 which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed as STAR-001 for pediatric and adult CNS cancers through Starlight Therapeutics, Lantern\u2019s wholly owned CNS-focused subsidiary. withZeta.ai, Lantern\u2019s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.<\/p>\n
ABOUT withZeta.ai<\/b><\/p>\n
withZeta.ai<\/a> is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done. Knowledge work in oncology is migrating to AI co-scientists \u2014 autonomous systems that investigate, reason, and synthesize across the full breadth of scientific evidence. withZeta.ai<\/a> is that co-scientist: purpose-built for the biology, economics, and urgency of rare cancer drug development, and accessible to any researcher, anywhere. Built by Lantern Pharma (Nasdaq: LTRN). Learn more and subscribe at withZeta.ai<\/a>.<\/p>\n
FORWARD-LOOKING STATEMENTS<\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR\u00ae platform and withZeta.ai platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; the planned commercialization of our AI platforms including withZeta.ai and the expected market opportunity for AI co-scientist platforms; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR\u00ae platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.<\/p>\n
\nAny statements that are not statements of historical fact (including, without limitation, statements that use words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cmodel,\u201d \u201cobjective,\u201d \u201caim,\u201d \u201cupcoming,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR\u00ae AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, (vii) the risk that our AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the expected market adoption, and (viii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.<\/p>\n
\nYou may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com<\/a> or on the SEC\u2019s website at www.sec.gov<\/a>. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260424944945\/en\/<\/a><\/span><\/p>\n
- Registration: <\/b>Register for Afternoon Session<\/a><\/li>\n<\/ul>\n
- Registration: <\/b>Register for Morning Session<\/a><\/li>\n<\/ul>\n
- Afternoon Session: <\/b>4:30 PM ET \u2014 Register Here<\/a><\/li>\n<\/ul>\n
- Morning Session: <\/b>8:30 AM ET \u2014 Register Here<\/a><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260424944945\/en\/1827644\/3\/Lanternlogo_square.jpg\")
<\/td>\n<\/tr>\n